PBYI

Puma Biotechnology Inc

8.25

Nov 06 • 3:59 PM ET -1.52 (-15.56%)

7.96

Aftermarket • 7:30 PM ET -0.29 (-3.50%)

Healthcare Biotechnology USA Small NASD

Nov 05, 7:16 PMPuma Biotechnology Q3 2026 non-GAAP EPS $0.11 (-35% YoY), revenue $54.1M (+4% YoY) and raises 2026 net income outlook to $20–22M

Peers: OLMA CELC ZYME ARVN VSTM KURA RIGL SNDX FENC AZN

| Held by: AVUV VTI IWM VXF DFAT DFAS IWN VTWO BSVO FESM

Scroll to Statements

Index	RUT
Market Cap	425.87M
Enterprise Value	317.37M
Income	23.87M
Sales	231.87M
Book/sh	2.71
Cash/sh	2.10
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	179
IPO	Apr 20, 2012

P/E	18.10
Forward P/E	-
PEG	-
P/S	1.84
P/B	3.04
P/C	3.93
P/FCF	10.35
EV/EBITDA	7.78
EV/Sales	1.37
Quick Ratio	2.64
Current Ratio	2.91
Debt/Eq	0.00
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	0.46
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	0.05% 0.29%
EPS Y/Y TTM	-37.03%
Sales Y/Y TTM	9.37%
EPS Q/Q	-34.91%
Sales Q/Q	1.15%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	- -

Insider Own	22.35%
Insider Trans	-1.78%
Inst Own	67.59%
Inst Trans	2.45%
ROA	13.78%
ROE	18.23%
ROIC	16.71%
Gross Margin	76.90%
Oper. Margin	11.28%
Profit Margin	10.30%
SMA20	-20.52%
SMA50	-16.46%
SMA200	3.21%
Trades

Shs Outstand	51.62M
Shs Float	40.08M
Short Float	11.33%
Short Ratio	13.26
Short Interest	4.54M
52W High	11.50 -28.26%
52W Low	4.57 80.33%
Volatility	7.56% 5.07%
ATR (14)	0.61
RSI (14)	30.38
Beta	1.35
Rel Volume	3.74
Avg Volume	342.30K
Volume	1,279,924

Perf Week	-20.98%
Perf Month	-17.25%
Perf Quarter	-5.06%
Perf Half Y	10.15%
Perf YTD	38.66%
Perf Year	68.37%
Perf 3Y	193.59%
Perf 5Y	105.74%
Perf 10Y	-77.21%
Recom	3.00
Target Price	6.00
Prev Close	9.77
Price	8.25
Change %	-15.56%

Consensus

Hold

Avg. Price Target

$6.00

Implied Upside

-27.3%

Analysts10incl. previous ratings

Rating Distribution3 Buy · 4 Hold · 3 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 28, 2021	Upgrade	CCitigroup	Neutral → Buy	$11	+33.3%
Jun 25, 2020	Resumed	BBofA/Merrill	Underperform	$9	+9.1%
Oct 08, 2019	Downgrade	GGoldman	Neutral → Sell	$24 → $8	-3.0%
May 10, 2019	Downgrade	CCitigroup	Buy → Neutral	$24	+190.9%
May 10, 2019	Downgrade	CCantor Fitzgerald	Overweight → Neutral	$57 → $20	+142.4%
Jan 17, 2019	Initiated	LLeerink Partners	Mkt Perform	$21	+154.5%
Jan 03, 2019	Downgrade	GGuggenheim	Buy → Neutral
Nov 19, 2018	Upgrade	GGoldman	Sell → Neutral
Nov 02, 2018	Downgrade	JJP Morgan	Neutral → Underweight
Nov 02, 2018	Downgrade	BBofA/Merrill	Buy → Underperform
Oct 01, 2018	Initiated	CCantor Fitzgerald	Overweight	$75	+809.1%
Sep 17, 2018	Initiated	GGoldman	Sell	$42	+409.1%
May 11, 2018	Reiterated	SStifel	Buy	$95 → $87	+954.5%
Nov 10, 2017	Reiterated	RRBC Capital Mkts	Sector Perform	$92 → $108	+1,209.1%
Nov 10, 2017	Reiterated	CCitigroup	Buy	$156 → $164	+1,887.9%
Oct 02, 2017	Reiterated	SStifel	Buy	$110 → $130	+1,475.8%
Sep 11, 2017	Reiterated	CCredit Suisse	Outperform	$118 → $136	+1,548.5%
Jul 10, 2017	Resumed	LLeerink Partners	Outperform	$115	+1,293.9%
Jun 06, 2017	Reiterated	RRBC Capital Mkts	Sector Perform	$60 → $88	+966.7%
May 25, 2017	Reiterated	RRBC Capital Mkts	Sector Perform	$40 → $60	+627.3%

Nov-05-26 05:48PM	Puma Biotechnology's Profit Beat And Raised Outlook Mask A Sequential Nerlynx Demand Slide (Earnings Whispers) -8.61% -15.56%
05:17PM	Puma Biotech: Q3 Earnings Snapshot (Associated Press)
03:05PM	Puma Biotechnology Reports Third Quarter 2026 Financial Results (Business Wire)
Nov-04-26 04:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-28-26 08:39PM	Puma Biotechnology's Nerlynx Rebound Faces Proof Test As Rally Lifts The Bar (Earnings Whispers)
04:11PM	Loading…
Oct-22-26 04:11PM	Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results (Business Wire)
Oct-05-26 05:00PM	Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-17-26 04:07PM	Puma Biotechnology Initiates ALISCA-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer (Business Wire)
Sep-09-26 04:11PM	Puma Biotechnology to Present at H.C. Wainwrights 28th Annual Global Investment Conference (Business Wire)
Sep-03-26 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-07-26 01:10AM	Puma Biotechnology Inc (PBYI) (Q2 2026) Earnings Call Highlights: Debt-Free Status and Raised ... (GuruFocus.com) +9.73%
Aug-06-26 05:22PM	Puma Biotech: Q2 Earnings Snapshot (Associated Press)
Aug-05-26 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-23-26 04:10PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results (Business Wire)
Jul-02-26 05:03PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
05:00PM	Loading…
Jun-03-26 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-07-26 05:37PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press)
04:05PM	Puma Biotechnology Reports First Quarter 2026 Financial Results (Business Wire)
May-06-26 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-23-26 04:15PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results (Business Wire)
Apr-02-26 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-26 12:35PM	PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View (Zacks) -25.00%
01:12AM	Puma Biotechnology Q4 Earnings Call Highlights (MarketBeat)
12:05AM	Puma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Feb-26-26 06:45PM	Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates (Zacks)
05:15PM	Puma Biotech: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-24-26 07:30PM	Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates (Zacks) +5.34%
Feb-23-26 04:15PM	Puma Biotechnology to Present at TD Cowens 46th Annual Health Care Conference (Business Wire)
Feb-12-26 04:07PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
05:25PM	Loading…
Feb-10-26 05:25PM	Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-04-26 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-07-26 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-31-25 11:20AM	Up 91% in the Past Year, Is This Biotech Stock Red Hot or a Red Flag? (Barchart)
Dec-22-25 04:10PM	Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI) (Business Wire)
Dec-17-25 11:26AM	CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
Dec-02-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.57%
Nov-27-25 11:58AM	IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? (Zacks)
Nov-07-25 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +22.24% -21.04%
10:53AM	PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised (Zacks)
12:03AM	Puma Biotechnology Inc (PBYI) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Royalty ... (GuruFocus.com)
Nov-06-25 06:00PM	Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates (Zacks)
04:55PM	Puma Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-05-25 05:20PM	Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-23-25 04:10PM	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Business Wire)
Oct-09-25 05:06AM	CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains? (Zacks)
Oct-02-25 05:21PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-17-25 02:27PM	What Do Analysts Think About Puma Biotechnology (PBYI)? (Insider Monkey)
Sep-15-25 12:42PM	PBYI Surges 30% in 3 Months: How Should You Play the Stock? (Zacks)
Sep-04-25 05:25PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-02-25 04:07PM	Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Sep-01-25 09:55AM	Puma Biotech (PBYI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-28-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Aug-13-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? (Zacks) +8.83%
Aug-12-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
09:15AM	Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out? (Zacks)
09:11AM	Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT (Insider Monkey)
Aug-08-25 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.16% +31.44%
10:26AM	PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues (Zacks)
Aug-07-25 05:55PM	Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:56PM	Puma Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Second Quarter Financial Results (Business Wire)
Aug-06-25 06:05PM	Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-24-25 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results (Business Wire)
Jul-15-25 08:31AM	Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns (Zacks)
Jul-14-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
Jul-10-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
Jul-08-25 10:31AM	Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease (Zacks)
Jul-04-25 08:35AM	AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer (Zacks)
Jul-02-25 05:03PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:34AM	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek (Zacks)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks)
10:05AM	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B (Zacks)
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks)
Jun-25-25 11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 08:50AM	Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain (Zacks)
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
Jun-12-25 11:30AM	Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? (Zacks)
Jun-11-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Jun-04-25 05:33PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.39%
May-28-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
May-26-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
May-12-25 08:50AM	Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock (Zacks)
May-09-25 09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks) -5.21%
08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
03:39AM	Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
May-08-25 05:55PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates (Zacks)
04:52PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
May-07-25 05:20PM	Puma Biotechnology Q1 2025 Earnings Preview (Seeking Alpha)
01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
08:10AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-05-25 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
May-01-25 08:05AM	Biogen Inc. (BIIB) Q1 Earnings Lag Estimates (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILSON TROY EDWARD	Director	Sep 14 '26	Sale	9.10	5,000	45,500	54,750	Sep 16 09:13 PM
Cesano Alessandra	Director	Sep 14 '26	Option Exercise	2.93	50,000	146,500	118,850	Sep 16 09:06 PM
Cesano Alessandra	Director	Sep 14 '26	Sale	9.12	62,150	566,994	56,700	Sep 16 09:06 PM
Cesano Alessandra	Director	Sep 14 '26	Proposed Sale	9.10	62,150	565,565		Sep 14 12:05 PM
WILSON TROY EDWARD	Director	Sep 14 '26	Proposed Sale	9.10	5,000	45,500		Sep 14 12:01 PM
AUERBACH ALAN H	President and CEO	Jul 06 '26	Sale	8.26	44,058	364,051	7,261,671	Jul 08 08:21 PM
HUNT DOUGLAS M	See Remarks	Jul 06 '26	Sale	8.26	8,460	69,905	196,841	Jul 08 08:19 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 06 '26	Sale	8.26	9,386	77,557	230,637	Jul 08 08:18 PM
AUERBACH ALAN H	Officer	Jul 06 '26	Proposed Sale	8.26	44,058	364,042		Jul 06 04:56 PM
HUNT DOUGLAS M	Officer	Jul 06 '26	Proposed Sale	8.26	8,460	69,903		Jul 06 04:49 PM
NOUGUES MAXIMO F	Officer	Jul 06 '26	Proposed Sale	8.26	9,386	77,555		Jul 06 04:44 PM
WILSON TROY EDWARD	Director	Jun 12 '26	Sale	7.20	10,800	77,748	59,750	Jun 15 08:16 PM
Stuglik Brian M	Director	Jun 12 '26	Sale	7.20	8,100	58,311	113,858	Jun 15 08:14 PM
Senderowicz Adrian	Director	Jun 12 '26	Sale	7.20	27,000	194,311	27,000	Jun 15 08:13 PM
MOYES JAY M	Director	Jun 12 '26	Sale	7.22	22,000	158,796	58,322	Jun 15 08:10 PM
Dorval Allison	Director	Jun 12 '26	Sale	7.20	11,610	83,579	90,780	Jun 15 08:09 PM
Senderowicz Adrian	Director	Jun 12 '26	Proposed Sale	7.26	27,000	196,020		Jun 12 10:39 AM
MOYES JAY M	Director	Jun 12 '26	Proposed Sale	7.26	22,000	159,720		Jun 12 10:37 AM
Dorval Allison	Director	Jun 12 '26	Proposed Sale	7.26	11,610	84,289		Jun 12 10:33 AM
Stuglik Brian M	Director	Jun 12 '26	Proposed Sale	7.26	8,100	58,806		Jun 12 10:23 AM
WILSON TROY EDWARD	Director	Jun 12 '26	Proposed Sale	7.26	10,800	78,408		Jun 12 09:58 AM
AUERBACH ALAN H	President and CEO	Jan 07 '26	Sale	5.88	18,012	105,893	7,145,951	Jan 08 08:27 PM
AUERBACH ALAN H	President and CEO	Jan 06 '26	Sale	5.84	16,938	98,986	7,163,963	Jan 08 08:27 PM
HUNT DOUGLAS M	See Remarks	Jan 07 '26	Sale	5.88	5,014	29,477	155,907	Jan 08 08:15 PM
HUNT DOUGLAS M	See Remarks	Jan 06 '26	Sale	5.84	3,973	23,218	160,921	Jan 08 08:15 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 07 '26	Sale	5.88	6,405	37,655	193,284	Jan 08 08:14 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 06 '26	Sale	5.84	4,540	26,532	199,689	Jan 08 08:14 PM
AUERBACH ALAN H	Officer	Jan 07 '26	Proposed Sale	5.88	18,012	105,893		Jan 07 04:28 PM
HUNT DOUGLAS M	Officer	Jan 07 '26	Proposed Sale	5.88	5,014	29,477		Jan 07 04:25 PM
NOUGUES MAXIMO F	Officer	Jan 07 '26	Proposed Sale	5.88	6,405	37,655		Jan 07 04:24 PM
NOUGUES MAXIMO F	Officer	Jan 06 '26	Proposed Sale	5.84	4,540	26,530		Jan 06 04:53 PM
HUNT DOUGLAS M	Officer	Jan 06 '26	Proposed Sale	5.84	3,973	23,217		Jan 06 04:45 PM
AUERBACH ALAN H	Officer	Jan 06 '26	Proposed Sale	5.84	16,938	98,979		Jan 06 04:44 PM
MILLER MICHAEL PATRICK	Director	Nov 11 '25	Sale	4.86	20,000	97,228	54,000	Nov 13 04:41 PM
MILLER MICHAEL PATRICK	Director	Nov 11 '25	Proposed Sale	4.86	20,000	97,228		Nov 12 08:29 AM

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

FounderMr. Alan H. Auerbach

CFO & Principal Accounting OfficerMr. Maximo F. Nougues

FRAPSMr. Douglas Hunt B.Sc.

Chief Accounting OfficerMr. Gordon G. Esplin

Senior Director of Investor RelationsMr. Mariann Ohanesian

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PBYI

Puma Biotechnology Inc

Upgrade your Finviz experience